{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}],"title":"Complete Response (CR)"},{"categories":[{"measurements":[{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}],"title":"Partial Repsonse (PR)"},{"categories":[{"measurements":[{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"}]}],"title":"Stable Disease (SD)"},{"categories":[{"measurements":[{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}]}],"title":"Progressive Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"description":"Tumor Response Rate by EORTC Criteria Tumor response rates were assessed from position emission tomography (PET) scans using 18F-FPPRGD2 \\& 18F-FDG at baseline \\& after 6 weeks of treatment, per European Organization for Research \\& Treatment of Cancer (EORTC) response criteria. The outcome is reported for each radiotracer by disease group as the number of participants achieving complete response (CR), partial response (PR), stable disease (SD), \\& progressive disease (PD).\n\n* CR= complete resolution of 18F-FDG uptake tumor volume\n* PR= reduction of 15-25% in tumor 18F-FDG SUVmax after 1 cycle of chemotherapy, and ≥25% after \\>1 cycle\n* SD= increase in tumor 18F-FDG SUVmax of \\<25% or a decrease of \\<15% \\& no increase in 18F-FDG tumor uptake \\[\\>20% in the longest dimension (LD)\\];\n* PD= increase in 18F-FDG tumor SUVmax of \\>25% in tumor region on baseline; increase in extent of 18F-FDG tumor uptake (\\>20% in LD); appearance of new 18F-FDG uptake in metastatic lesions","groups":[{"description":"Patients with glioblastoma multiforme (GBM) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and 6 weeks (or standard of care follow-up)\n\n18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan\n\n18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2.","id":"OG000","title":"Glioblastoma Multiforme (GBM)"},{"description":"Patients with gynecological cancer undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)\n\n18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan\n\n18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2.","id":"OG001","title":"Gynecological Cancers"},{"description":"Patients with renal cell cancer (RCC) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)\n\n18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan\n\n18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2.","id":"OG002","title":"Renal Cell Cancer (RCC)"}],"paramType":"NUMBER","populationDescription":"This assessment was restricted to gynecological cancers and renal cell carcinoma participants only. Tumor response data was not available for all participants in these groups.","reportingStatus":"POSTED","timeFrame":"At baseline and 6 weeks","title":"Tumor Response Rate by EORTC Criteria","type":"SECONDARY","unitOfMeasure":"participants"}